Curis Inc

NASDAQ:CRIS USA Biotechnology
Market Cap
$12.25 Million
Market Cap Rank
#28632 Global
#9529 in USA
Share Price
$0.89
Change (1 day)
+3.93%
52-Week Range
$0.83 - $2.80
All Time High
$370.00
About

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodyspla… Read more

Curis Inc (CRIS) - Total Liabilities

Latest total liabilities as of September 2025: $42.33 Million USD

Based on the latest financial reports, Curis Inc (CRIS) has total liabilities worth $42.33 Million USD as of September 2025.

Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Curis Inc - Total Liabilities Trend (1999–2024)

This chart illustrates how Curis Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.

Curis Inc Competitors by Total Liabilities

The table below lists competitors of Curis Inc ranked by their total liabilities.

Company Country Total Liabilities
Centrale d'Achat Française pour l'Outre-Mer Société Anonyme
PA:CAFO
France €250.52 Million
Global SM Tech Limited
KQ:900070
Korea ₩35.90 Billion
DIC India Limited
NSE:DICIND
India ₹1.94 Billion
Youngtimers AG
SW:YTME
Switzerland CHF69.32 Million
Charnic Capital Tbk PT
JK:NICK
Indonesia Rp2.91 Billion
Tigers Realm Coal Ltd
AU:TIG
Australia AU$46.17 Million
SSH Communications Security Oyj
HE:SSH1V
Finland €17.20 Million

Liability Composition Analysis (1999–2024)

This chart breaks down Curis Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.70 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity -2.88 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 1.53 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Curis Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Curis Inc (1999–2024)

The table below shows the annual total liabilities of Curis Inc from 1999 to 2024.

Year Total Liabilities Change
2024-12-31 $47.26 Million -17.96%
2023-12-31 $57.61 Million -7.52%
2022-12-31 $62.30 Million -12.99%
2021-12-31 $71.59 Million -2.84%
2020-12-31 $73.69 Million +6.77%
2019-12-31 $69.02 Million +64.87%
2018-12-31 $41.86 Million -15.95%
2017-12-31 $49.80 Million +74.84%
2016-12-31 $28.49 Million -6.46%
2015-12-31 $30.45 Million -7.24%
2014-12-31 $32.83 Million -7.31%
2013-12-31 $35.42 Million -0.83%
2012-12-31 $35.71 Million +330.06%
2011-12-31 $8.30 Million +61.83%
2010-12-31 $5.13 Million +68.41%
2009-12-31 $3.05 Million +10.51%
2008-12-31 $2.76 Million -60.45%
2007-12-31 $6.97 Million -57.41%
2006-12-31 $16.37 Million -28.56%
2005-12-31 $22.91 Million +22.37%
2004-12-31 $18.73 Million +10.99%
2003-12-31 $16.87 Million -61.57%
2002-12-31 $43.90 Million +0.37%
2001-12-31 $43.74 Million +215.37%
2000-12-31 $13.87 Million +153.50%
1999-12-31 $5.47 Million --